Skip to main content

Table 1 Clinical background of studies included in the meta-analysis

From: Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma

Reference Year Inclusion Period Country Group No. of patients M/F Mean age (years) Mean AFP (ng/ml) Child-Pugh A/B/C LB N/H/C Tumor size (cm) Matching Not matching Score
RCTs               
Wu [14] 1995 1983-1991 Taiwan TACE (+) TACE (−) 24 28 23/1 23/5 51.8 ± 12.4 53.2 ± 11.5 ≥ 400 (n = 15) ≥ 400 (n = 16) 22/2/0 24/4/0 —/—/14 —/—/12 14.3 ± 4.2 14.5 ± 3.3 1-3,5-15 17 2
Yamasaki [15] 1996 1987-1989 Japan TACE (+) TACE (−) 50 47 50/0 47/0 54.9 ± 6.4 57.1 ± 4.9 — — — — —/—/— —/—/— 3.1 ± 0.8 3.3 ± 0.9 1,2,4,9-12 2
Zhou [16] 2009 2001-2003 China TACE (+) TACE (−) 52 56 48/4 49/7 45.3 ± 9.8 46.8 ± 9.6 1244.2 ± 376 1387.5 ± 426 44/8/0 54/2/0 —/—/49 —/—/50 9.0 ± 3.2 9.5 ± 3.9 1-3,5-10, 12,14,15 3
Kaibori [24] 2012 2004-2007 Japan TACE (+) TACE (−) 42 43 35/7 32/11 68.1 ± 5.7 66.1 ± 10.6 2432 ± 11638 858 ± 5269 37/5/0 39/4/0 1/27/14 4/28/11 4.3 ± 2.1 4.8 ± 4.1 1-10,12, 13,15 11 3
NRCTs               
Nagasue [12] 1989 1980-1986 Japan TACE (+) TACE (−) 31 107 25/6 90/17 56.5 ± 9.1 59.4 ± 8.9 >20 (n = 18) >20 (n = 76) 17/13/1 69/32/6 —/—/26 —/—/88 >3 (n = 17) >3 (n = 72) 1-3,5,6, 8–11,14 19
Adachi [13] 1993 1981-1991 Japan TACE (+) TACE (−) 46 26 39/7 21/5 55.9 ± 7.71 59.8 ± 5.7 >20 (n = 24) >20 (n = 15) — — —/—/29 —/—/22 2.6 ± 0.9 2.1 ± 0.9 2-4,6-8,11,14,16 1,9,13 18
Harada [28] 1996 1982-1994 Japan TACE (+) TACE (−) 105 35 90/15 30/5 57.6 ± 9.7 59.8 ± 9.9 — — — — —/—/69 —/—/24 >5 (n = 36) >5 (n = 9) 1,2,4,7-10,12 19
Uchida [29] 1996 1986-1991 Japan TACE (+) TACE (−) 60 68 50/10 52/16 59.0 ± 9.9 62.0 ± 7.2 >20 (n = 27) >20 (n = 45) 37/18/5 45/18/5 —/—/42 —/—/49 3.7 ± 3.1 4.4 ± 3.4 2,4-10,14 1,3,11,13 18
Majno [10] 1997 1985-1995 France TACE (+) TACE (−) 49 27 44/5 26/1 59.2 ± 7.1 60.9 ± 7.8 285 ± 1629 129 ± 250 43/6/0 17/10/0 0/0/49 0/0/27 5.05 ± 2.5 3.9 ± 1.8 1-3,8,10, 12-14 5-7 18
Di Carlo [11] 1998 1989-1997 Italy TACE (+) TACE (−) 55 45 49/6 34/11 63.0 ± 6.0 62.0 ± 6.0 >10 (n = 13) >100 (n = 6) 48/—/— 36/—/— 0/0/55 0/0/45 >3 (n = 32) >3 (n = 31) 1-3,5,7-12,14,15 13 18
Paye [30] 1998 1986-1992 France TACE (+) TACE (−) 24 24 21/3 17/7 57 ± 2 54 ± 3 2560 (2–46000) 4229 (2–73000) 22/2 22/2 1/—/13 1/—/13 7.8 ± 1 7.3 ± 1 1-3,5-10,12-14,16 17
Lu [31] 1999 1988-1994 China, Japan TACE (+) TACE (−) 44 76 36/8 57/19 51.5 54.5 — — 31/13/0 61/15/0 —/—/28 —/—/44 7.3 7.6 2,5,6,8,9,11,14 1 20
Ochiai [32] 2003 1978-1994 Japan TACE (+) TACE (−) 100 48 78/22 43/5 59.6 ± 8 58.9 ± 8.7 >400 (n = 74) >400 (n = 30) — — —/—/— —/—/— 4.4 ± 3.3 4.4 ± 3.1 1-4,6,7,9, 10,12-15 20
Sugo [33] 2003 1997-2000 Japan TACE (+) TACE (−) 146 81 122/24 67/14 57.6 ± 9.4 60.5 ± 9 — — 118/27/1 74/6/1 —/—/116 —/—/58 4.5 ± 3.0 4.8 ± 3.9 2,5,8,9 1 18
Sasaki [34] 2006 1982-2003 Japan TACE (+) TACE (−) 109 126 85/24 97/29 >65 (n = 38) >65 (n = 68) >100 (n = 40) >100 (n = 49) — — —/—/76 —/—/61 ≥5 (n = 27) ≥5 (n = 47) 2-4,7,9,11, 12 1,8 20
Chen [35] 2007 1990-2004 China TACE (+) TACE (−) 89 157 71/18 136/21 45.5 ± 6.3 48.6 ± 5.7 2838 ± 1721 2335 ± 1088 78/11/0 142/15/0 —/—/15 —/—/25 9.5 ± 2.6 9.9 ± 3.1 1-3,6-10,12,13,16 20
Choi [36] 2007 1998-2005 Korea TACE (+) TACE (−) 120 153 93/27 117/36 52.4 ± 9.6 52.4 ± 10.4 8094 ± 68967 2292 ± 7444 117/0/0 150/2/0 —/—/56 —/—/75 >5 (n = 44) >5 (n = 50) 1-6,8-10,12-14 7 19
Kim [37] 2008 1995-2000 Korea TACE (+) TACE (−) 97 237 80/17 194/43 48.8 ± 9.2 51.7 ± 10.2 >1000 (n = 70) >1000 (n = 31) 97 237 —/—/77 —/—/182 >5 (n = 49) >5 (n = 101) 1-3,5-10,12,14 16 19
Lee [38] 2009 2000-2006 Taiwan TACE (+) TACE (−) 114 236 89/25 173/63 57.9 ± 11.3 57.8 ± 11.7 2265.88 ± 8438.55 1862.52 ± 1388.63 110/4/0 232/4/0 —/—/79 —/—/152 4.3 ± 3.1 3.9 ± 2.7 1-3,5,7-10, 12,15 11 18
Kang [39] 2010 1997-2007 Korea TACE (+) TACE (−) 32 64 25/7 51/13 52.4 ± 9.8 54.0 ± 10.8 9584.4 ± 26238.5 5100.9 ± 24773.9 30/2/0 64/0/0 —/—/— —/—/— 4.3 ± 2.5 4.5 ± 3.2 1-3,5,6,9,10,15 20
Yamashita [40] 2012 1995-2008 Japan TACE (+) TACE (−) 42 95 36/7 77/18 58 ± 12 64 ± 9 1527 ± 4415 1125 ± 4713 31/—/— 88/—/— —/—/7 —/—/26 9.1 ± 3.2 7.9 ± 3.0 2-4,7-11 1,5,6 20
  1. LB liver background; N/H/C normal/hepatitis/cirrhosis; 1, Age; 2, Gender; 3, AFP level; 4, ICG R15 (%); 5, Child-Pugh grade; 6, Viral status; 7, Operative procedures; 8, LB; 9, Tumor size; 10 Tumor number;11, Histologic grade; 12,Vascular invasion; 13, Tumor encapsulation; 14, Intrahepatic metastasis or satellite nodules; 15, Pathological stage; 16,Capsular invasion;17, Adjacent organ invasion.